Literature DB >> 33468480

Variability of Hydroxy-Itraconazole in Relation to Itraconazole Bloodstream Concentrations.

Nathan P Wiederhold1, Ilan S Schwartz2, Thomas F Patterson3,4, George R Thompson5,6,7.   

Abstract

We analyzed the relationship between itraconazole (ITZ) and hydroxy-itraconazole (OH-ITZ) levels in 1,223 human samples. Overall, there was a statistically significant correlation between ITZ and OH-ITZ levels (Pearson's r, 0.7838), and OH-ITZ levels were generally higher than ITZ levels (median OH-ITZ:ITZ ratio, 1.73; range, 0.13 to 8.96). However, marked variability was observed throughout the range of ITZ concentrations. Thus, it is difficult to predict OH-ITZ concentrations based solely on ITZ levels.
Copyright © 2021 American Society for Microbiology.

Entities:  

Keywords:  TDM; antifungal efficacy; bioassay; bloodstream concentrations; hydroxy-itraconazole; itraconazole; therapeutic-drug monitoring

Year:  2021        PMID： 33468480      PMCID： PMC8097436          DOI： 10.1128/AAC.02353-20

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  26 in total

1.  Antifungal activity of itraconazole compared with hydroxy-itraconazole in vitro.

Authors:  F C Odds; H V Bossche
Journal:  J Antimicrob Chemother       Date:  2000-03       Impact factor: 5.790

2.  Toxicodynamics of itraconazole: implications for therapeutic drug monitoring.

Authors:  Jodi M Lestner; Steven A Roberts; Caroline B Moore; Susan J Howard; David W Denning; William W Hope
Journal:  Clin Infect Dis       Date:  2009-09-15       Impact factor: 9.079

Review 3.  Therapeutic drug monitoring of systemic antifungal therapy.

Authors:  K K Summers; T C Hardin; S J Gore; J R Graybill
Journal:  J Antimicrob Chemother       Date:  1997-12       Impact factor: 5.790

4.  Breakthrough invasive fungal infections in neutropenic patients after prophylaxis with itraconazole.

Authors:  A Glasmacher; C Hahn; C Leutner; E Molitor; E Wardelmann; C Losem; T Sauerbruch; G Marklein; I G Schmidt-Wolf
Journal:  Mycoses       Date:  1999       Impact factor: 4.377

5.  Itraconazole therapy for nonmeningeal coccidioidomycosis: clinical and laboratory observations.

Authors:  R M Tucker; D W Denning; E G Arathoon; M G Rinaldi; D A Stevens
Journal:  J Am Acad Dermatol       Date:  1990-09       Impact factor: 11.527

6.  A double-blind, randomized, placebo-controlled trial of itraconazole capsules as antifungal prophylaxis for neutropenic patients.

Authors:  M Nucci; I Biasoli; T Akiti; F Silveira; C Solza; G Barreiros; N Spector; A Derossi; W Pulcheri
Journal:  Clin Infect Dis       Date:  2000-02       Impact factor: 9.079

7.  Bioassay for serum itraconazole concentrations using hydroxyitraconazole standards.

Authors:  D Law; C B Moore; D W Denning
Journal:  Antimicrob Agents Chemother       Date:  1994-07       Impact factor: 5.191

8.  Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America.

Authors:  Thomas F Patterson; George R Thompson; David W Denning; Jay A Fishman; Susan Hadley; Raoul Herbrecht; Dimitrios P Kontoyiannis; Kieren A Marr; Vicki A Morrison; M Hong Nguyen; Brahm H Segal; William J Steinbach; David A Stevens; Thomas J Walsh; John R Wingard; Jo-Anne H Young; John E Bennett
Journal:  Clin Infect Dis       Date:  2016-06-29       Impact factor: 9.079

9.  A reference laboratory experience of clinically achievable voriconazole, posaconazole, and itraconazole concentrations within the bloodstream and cerebral spinal fluid.

Authors:  Nathan P Wiederhold; Gennethel J Pennick; Sheryl A Dorsey; Wieslaw Furmaga; James S Lewis; Thomas F Patterson; Deanna A Sutton; Annette W Fothergill
Journal:  Antimicrob Agents Chemother       Date:  2013-11-04       Impact factor: 5.191

Review 10.  Therapeutic drug monitoring (TDM) of antifungal agents: guidelines from the British Society for Medical Mycology.

Authors:  H Ruth Ashbee; Rosemary A Barnes; Elizabeth M Johnson; Malcolm D Richardson; Rebecca Gorton; William W Hope
Journal:  J Antimicrob Chemother       Date:  2013-12-29       Impact factor: 5.790
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.